Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms. Issue 2 (20th December 2020)

• Record Type: Journal Article
• Authors: Sagou, Ken; Ito, Makoto; Kawamura, Yuma; Ukai, Shun; Goto, Miyo; Fukushima, Nobuaki; Ozeki, Kazutaka; Fukuyama, Ryuichi; Kohno, Akio
• Is Part Of: Clinical case reports. Volume 9:Issue 2(2021)
• Page Start: 878
• Page End: 882
• Publication Date: 2020-12-20
• Subjects: calreticulin mutation -- myelodysplastic/myeloproliferative neoplasms -- plasmacytoid dendritic cell neoplasm -- tumor lysis syndrome; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.3690
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS. Abstract : BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.